Biovica International (BIOVIC) Q4 24/25 earnings summary

Executive summary

• Achieved key milestones including FDA 510(k) clearance, Medicare inclusion, and major partnerships in the US and Europe, positioning for significant commercial expansion.

• US sales up 120% year-over-year and over 30% sequentially in Q4, with strong momentum into the new fiscal year.

• Signed major agreements with Tempus AI, a large US healthcare giant, and Eurobio Scientific, covering 60% of key European markets.

• DiviTum test demonstrated strong clinical value in metastatic and early breast cancer, supported by robust clinical evidence from over 30 trials and presentations at major conferences.

• Rights issue of approximately SEK 80 million fully guaranteed to fund commercialization and expansion.

Financial highlights

• Year-to-date net sales reached SEK 8.6 million, up 20% year-over-year, with US sales as the primary growth driver.

• Q4 US sales were nearly SEK 3 million, representing 275% growth year-over-year.

• Operating loss for Q4 was SEK -20.3 million, a significant improvement from SEK -41.5 million last year.

• Net operating cash flow improved by SEK 8.5 million year-over-year due to cost reductions.

• Cash and cash equivalents at period end: SEK 24.4 million.

Outlook and guidance

• Revenue guidance: FY24/25 SEK 8.5 million, FY25/26 SEK 50 million, FY26/27 SEK 150 million, with the US as the largest contributor.

• Break-even targeted for Q3 of fiscal year 2026-2027 (January 2027), with current and planned financing expected to cover needs until then.

• Tempus AI and healthcare giant agreements expected to be main US revenue drivers; Europe expected to contribute SEK 1 million next year and SEK 10 million the following year.